# Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

> **NCT00926107** · PHASE2 · TERMINATED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 9 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00926107
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment
- **Last updated:** 2011-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00926107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00926107, "Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00926107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*